Background: Atopic diseases, including asthma, exacerbate type 2 immune responses and involve a number of immune cell types, including regulatory T (Treg) cells and the emerging type 2 innate lymphoid cells (ILC2s). Although ILC2s are potent producers of type 2 cytokines, the regulation of ILC2 activation and function is not well understood. Objective: In the present study, for the first time, we evaluate how Treg cells interact with pulmonary ILC2s and control their function. Methods: ILC2s and Treg cells were evaluated by using in vitro suppression assays, cell-contact assays, and gene expression panels. Also, human ILC2s and Treg cells were adoptively transferred into NOD SCID gC-deficient mice, which were given isotype or anti-inducible T-cell costimulator ligand (ICOSL) antibodies and then challenged with IL-33 and assessed for airway hyperreactivity. Results: We show that induced Treg cells, but not natural Treg cells, effectively suppress the production of the ILC2-driven proinflammatory cytokines IL-5 and IL-13 both in vitro and in vivo. Mechanistically, our data reveal the necessity of inducible T-cell costimulator (ICOS)-ICOS ligand cell contact for Treg cell-mediated ILC2 suppression alongside the suppressive cytokines TGF-b and IL-10. Using a translational
Asthma is an immunologic disease of chronic airway inflammation characterized by airway hyperreactivity (AHR) and reversible airflow obstruction 1, 2 and involving a variety of cell types, including regulatory T (Tregs) cells 3, 4 and type 2 innate lymphoid cells (ILC2s). 5 Type 2 cytokines, including IL-5 and IL-13, play a pivotal role in disease pathogenesis. IL-5 promotes proliferation of lung eosinophils, whereas IL-13 increases mucus production and contraction of airway smooth muscle cells. These reactive phenomena lead to the development of AHR, a cardinal feature of asthma. 6, 7 Although T H 2 CD4 T cells have classically been considered the main source of type 2 cytokines, such as IL-13 and IL-5, recent studies have shown that ILC2s also produce a type 2 immune response after exposure to stimuli known to induce AHR, such as IL-33, IL-25, or species from the ubiquitous fungal genus Alternaria. 5, [8] [9] [10] Indeed, ILC2s are sufficient to induce hallmarks of asthma in immunodeficient mice. Our group has previously shown that both human and murine ILC2s express both inducible T-cell costimulator (ICOS) and inducible T-cell costimulator ligand (ICOSL) and that ICOS-ICOSL interaction is necessary for ILC2 function and survival to promote AHR. 11 Conversely, we have shown that ICOS expression on Treg cells is necessary to inhibit AHR. 4 Thus we examined a potential ICOS/ICOSL interaction among ILC2s and T cells to regulate AHR.
Treg cells, a well-established subpopulation of CD4 1 T cells, have the capacity to mediate suppression in a variety of autoimmune and inflammatory conditions, including asthma. 4, 12 Depending on where they are generated, Treg cells are divided into 2 subpopulations: natural regulatory T (nTreg) cells (also known as tTregs), which arise in the thymus, and extrathymic or induced regulatory T (iTreg) cells (also known as pTregs), which are induced in the periphery. 13 Mice deficient in iTreg cells exhibit allergic inflammation within mucosal sites, specifically leading to pathology characteristic of asthma.
14 However, whether these T cells can modulate ILC2 effector numbers and function remains to be explored.
Here we found substantial suppressive effects of Treg cells on ILC2s in a murine model of asthma. We discovered that direct cell-cell contact was essential to the Treg cell-ILC2 interaction. Specifically, we suggest that ICOSL on ILC2s binds to ICOS on Treg cells. This ICOS-ICOSL interaction, alongside TGF-b and IL-10, is required for the regulation of ILC2s by Treg cells. By using humanized ILC2 mice, we found conservation of ICOSL-mediated ILC2 suppression by human Treg cells in vivo. Together, the findings uncover Treg cells as potent regulators of ILC2 activation.
METHODS Mice
BALB/cByJ, recombination-activating gene 2 (RAG2) 
ILC2 isolation
Lungs were aseptically removed, minced, and incubated in 1.6 mg/mL collagenase (CLS4; Worthington Biochemicals, Lakewood, NJ) at 378C for 90 minutes and pressed through a 70-mm filter mesh. ILC2s were identified as Lin 2 (CD3ε, CD11c, CD11b, B220, Ter-119, Gr-1, FcεRIa, and gd T-cell receptor), CD45 1 , CD127 
In vitro suppression assay
Purified Teff, nTreg, and iTreg cells were cocultured with ILC2s (5 3 10 3 cells/well) at indicated ratios: 2:1, 1:1, 1:2, and 1:4 for 48 hours in the presence of IL-2 (10 ng/mL) and IL-7 (10 ng/mL). IL-5 and IL-13 cytokine levels were measured in supernatants by means of ELISA (eBioscience). For blocking experiments, iTreg cells (10 4 ) and ILC2s (5 3 10 3 ) were cocultured at a 2:1 ratio in the presence or absence of neutralizing antibodies for IL-10 (10 mg/mL), TGF-b (10 mg/mL), IL-10 plus TGF-b, ICOS (10 mg/mL), or ICOSL (10 mg/mL; all obtained from Bio X Cell, West Lebanon, NH). Innate lymphoid cells alone were cultured for 48 hours in the presence or absence of recombinant IL-10 (10 ng/mL) and TGF-b (10 ng/mL), and cytokines were measured in supernatants. For intracellular flow cytometry, cells were restimulated with phorbol 12-myristate 12-acetate (5 ng/mL) and ionomycin (50 ng/mL) with the transport inhibitor Brefeldin A (1 ng/mL) 4 hours before staining with indicated antibody (eBioscience) with the transcription factor staining kit (eBioscience) or Annexin V staining kit (BD Biosciences) per the manufacturer's instructions. For transwell experiments, CD4
Foxp3
1 iTreg cells were cocultured with ILC2s (5 3 10 3 cells/well) in a Corning HTS 96-well Transwell (Corning, Corning, NY), according to manufacturer's instructions, in the presence of IL-2 (10 ng/mL) and IL-7 (10 ng/mL) for 48 hours. Staining antibody against ICOSL was purchased from BioLegend for the assessment of ICOSL expression on ILC2s.
For in vitro activation studies with rmICOS/Fc Chimera protein, activated pulmonary ILC2s were isolated as described above and incubated on a plate coated with reagents (either ICOS immunoglobulin or control immunoglobulin, 1 mg/mL; R&D Systems) for 48 hours in the presence of IL-2/IL-7. Culture supernatants were taken for cytokine measurement by using ELISA.
Bronchoalveolar lavage flow cytometry
Bronchoalveolar lavage (BAL) fluid was incubated with CD19 fluorescein isothiocyanate, Siglec-F PE, CD3 PerCP/Cy5, Gr-1 allophycocyanin, CD11c allophycocyanin/Cy7, CD45 PE/Cy7, CD11b eFluoro450, and Fc block (BioLegend). The cells were acquired on the FACSCanto and analyzed by using FlowJo software (Tree Star), as previously described. 15 Neutrophils were gated as CD45
1 , Gr-1 Asthma murine model and adoptive transfer of iTreg cells iTreg cells (9 3 10 5 cells) were adoptively transferred through tail vein injection (intravenous) into 6-to 8-week-old female Rag2 2/2 (BALB/cByJ) mice followed by 3 days of intranasal IL-33 (0.5 mg per mouse), Alternaria alternata (25 g per mouse; Greer Laboratories, Lenoir, NC), or PBS, as indicated. Lung function was measured 24 hours after the last injection by means of direct measurement of lung resistance and dynamic compliance in restrained, tracheostomized, mechanically ventilated mice by using the Finepointe RC System (Buxco Research System, Wilmington, NC) after achievement of general anesthesia, as described previously. 15 
Humanized mice
Purified human ILC2s were cultured with rhIL-2 (20 ng/mL) and rhIL-7 (20 ng/mL) for 3 days before adoptive transfer. ILC2s (2.5 3 10 4 cells per mouse), Teff cells (2.5 3 10 5 cells per mouse), and/or iTreg cells (2.5 3 10 5 cells per mouse) were then injected intravenously into 6-to 9-week-old female NSG mice, as indicated, followed by intranasal treatment with isotype control or anti-ICOSL antibodies (100 mg per mouse). Human anti-ICOSL antibodies were generated and provided by Dr Gordon Freeman, as described elsewhere. 4 After 24 hours, rhIL-33 (0.5 mg per mouse) was administered intranasally on 3 consecutive days, and lung function was measured 24 hours after the last treatment.
Gene expression analysis with NanoString nCounter technology
By using FACS sorting, ILC2s were purified from a cohort of wild-type mice after 3 serial intranasal IL-33 administrations. iTreg cells were generated, as described above. iTreg cells and ILC2s were cocultured at a 2:1 ratio, and after 24 hours, ILC2s were sorted from cocultures. Total RNA was isolated by using MicroRNAeasy (Qiagen, Valencia, Calif) and analyzed for gene expression by using the NanoString nCounter system (Seattle, Wash), as described by our group elsewhere.
11 mRNA counts within samples were normalized to an expression panel of 10 housekeeping genes, and differences in gene expression were calculated as a logarithmic ratio between ILC2s and ILC2/iTreg cell cocultures by using Bonferroni-adjusted P values.
Study approval
Animal studies were approved by the University of Southern California (USC) Institutional Animal Care and Use Committee and conducted in accordance with the USC Department of Animal Resources' guidelines. All human studies were approved by the USC Institutional Review Board and conducted according to the principles of the Declaration of Helsinki. Participants provided written informed consent before their inclusion in the study and were identified by number.
RESULTS iTreg cells, but not nTreg cells, suppress production of cytokines by ILC2s in vitro
We initially evaluated the ability of Treg cells to regulate ILC2s by using an in vitro suppression assay. Purified iTreg cells were generated in vitro from naive Foxp3 Fig E1 , B) ex vivo at different ratios. After 2 days in culture, ILC2s alone secreted large amounts of IL-5 and IL-13, as expected and as measured by using ELISA. In contrast, adding increasing numbers of iTreg cells substantially reduced cytokine production; in the 2:1 iTreg cell/ILC2 group, IL-5 and IL-13 levels were reduced 70.3% and 60.1%, respectively, compared with those in the ILC2 group alone (Fig 1, A) .
On the other hand, addition of neither nTreg cells from the thymus nor (non-Treg) Teff cells from the spleen suppressed IL-5 and IL-13 production by ILC2s (Fig 1, B and C) . These data suggest that the regulatory capacity exercised on ILC2s is distinctly attributed to iTreg cells.
iTreg cells attenuate induction of ILC2-dependent AHR in vivo
To assess the ability of iTreg cells to suppress ILC2s in vivo, we treated murine models of AHR, Rag2-deficient mice, intranasally with PBS, IL-33, or A alternata, a clinically relevant allergen that induces many inflammatory molecules, including IL-33, IL-25, and thymic stromal lymphopoietin (TSLP). 16 We then followed with intravenous administration of iTreg cells (schema in Fig 2,  A and D) . In mice treated with IL-33, adoptive transfer of iTreg cells reduced lung resistance compared with mice receiving only IL-33 (Fig 2, B) . The number of eosinophils in fluid obtained by using BAL was also decreased in the group that received adoptive transfer of iTreg cells (Fig 2, C) .
Importantly, both AHR and eosinophilia in A alternatasensitized mice were also reduced from iTreg cell transfer compared with that seen in ILC2s alone (Fig 2, E and F) . These findings show that iTreg cells are sufficient to suppress ILC2-dependent inflammation in vivo.
IL-10 and TGF-b are required for iTreg cell-induced suppression of ILC2s
To gain insight into how Treg cells suppressed ILC2s, we reisolated ILC2s using FACS after a 24-hour coculture with iTreg cells and then analyzed gene expression of a panel of immune-related genes using NanoString technology, as previously described. 11 Of more than 270 mRNAs measured in ILC2s, those that were modulated by iTreg cell addition are shown as logarithmic fold change (Fig 3, A) . This included downregulation of the cytokines Il5 and Il13, as well as Tgfb1, and the surface receptors Tgfbr1, Icos, and Il2ra (Fig 3, B) . We also found reduced levels of Gata3 in ILC2s cocultured with iTreg cells, which is pertinent given that GATA3 drives ILC2 function. 17 Because we found evidence of TGF-b1 signaling and IL-10 and TGF-b are 2 canonical inhibitory cytokines produced by Treg cells, 4, 18 we questioned whether TGF-b was required for the suppressive effect of iTreg cells. First, we cocultured ILC2s and iTreg cells with neutralizing antibodies against IL-10 and TGF-b1. In these cultures the presence of neutralizing antibodies for IL-10 and TGF-b abrogated the iTreg cell-induced suppression of IL-5 and IL-13 production by ILC2s (Fig 3, C) , confirming that suppression of ILC2s by iTreg cells is mediated by IL-10 and TGF-b. Some Treg cells express a form of membrane-bound TGF-b1, which is known as latency-associated peptide (LAP). 19 We asked whether blocking ICOS-ICOSL interaction could modulate the level of IL-10 expression or the percentage of LAP-expressing cells in cocultures of iTreg cells and ILC2s. Adding anti-ICOSL antibody to this system decreased both expression of IL-10, as measured by using ELISA, and LAP, as measured by using flow cytometry (see Fig E2, (Fig 2, B and E) , and BAL fluid eosinophil numbers were measured by using flow cytometry (Fig 2, C and F) . Data are expressed as means 6 SEMs (n 5 5). *P < .05, ***P < .001, and ****P < .0001.
In our preceding experiments TGF-b contributed the majority of suppression by Treg cells. To assess the expression of TGF-b by iTreg or nTreg cells, the presence of LAP on the cell surface was assessed by using flow cytometry. Although LAP was significantly expressed on iTreg cells, nTreg cells appeared to be LAP negative (Fig 3, D) , indicating that surface TGF-b is significantly produced by iTreg cells and might partially mediate the suppression exerted on ILC2s.
To further assess the role of TGF-b and IL-10 treatment, we cultured ILC2s in the presence of recombinant IL-10, recombinant TGF-b1, or both for 2 days and subsequently measured IL-5 and IL-13 levels in the supernatant. Our results indicated that IL-10 and TGF-b1 significantly reduced cytokine secretion by ILC2s (Fig 4, A) . We also performed the same experiments and assessed the proportion of IL-5-and IL-13-producing ILC2s by using flow cytometry after restimulation with phorbol The suppressive effect of iTreg cells is mediated by inhibitory cytokines. ILC2s were cultured in the presence of 10 ng/mL rTGF-b1, rIL-10, or both. A and B, IL-5 and IL-13 production was measured by using ELISA. C and D, Cultured ILC2s were also assessed for the expression of 7-aminoactinomycin (7AAD)/Annexin V (AnnV) and Ki67 by using flow cytometry. Data are presented as means 6 SEMs (n 5 4). *P < .05, **P < .005, and ***P < .0005. NT, Non-treated.
12-myristate 12-acetate and ionomycin (Fig 4, B) . This reduction in cytokine levels was not due to changes in apoptosis or proliferation, as measured by using Annexin V/7-aminoactinomycin and Ki67, respectively (Fig 4, C and D) . Our results further confirm that treatment with recombinant IL-10 and TGF-b1 significantly reduced cytokine secretion by ILC2s.
iTreg cell-suppressive effect on ILC2s requires ICOS-ICOSL cell-cell contact
Prior studies suggested that cell-cell contact is required for Treg cell-mediated suppression. 20 To analyze the contact dependency of the iTreg cell suppressive effect on ILC2s, we cultured both types of cells in a transwell stimulation assay. In conventional wells (allowing cell-cell contact) iTreg cells strongly suppressed secretion of IL-5 and IL-13 by ILC2s. In transwells not allowing cell-cell contact, the suppressive ability of iTreg cells is abrogated significantly with regard to IL-5 (Fig 5, A) . Furthermore, we observed similar suppressive capacity of iTreg cells on ILC2s after activation with IL-25 or TSLP (see Fig E2, B) . These data suggest that cell-cell contact is required for suppression of ILC2s by iTreg cells.
Given our recent finding that ICOS-ICOSL interaction is necessary for ILC2 function, 11 we next investigated whether the suppression of ILC2s by Treg cells is mediated by an interaction between ICOS on Treg cells and ICOSL on ILC2s. Adding anti-ICOSL (ICOS ligand blocking) antibody to cocultures of iTreg cells and ILC2s abrogated suppression of cytokine production normally seen with iTreg cells (Fig 5, B) . ICOS signaling has been suggested to be required for the suppressive activity of Treg cells, 13, 21 and it has been suggested that cell-cell contact boosts or potentiates Treg cell function. 22 To further assess the importance of ICOS-ICOSL interaction between Treg cells and ILC2s, we cocultured iTreg cells with ICOS 2/2 ILC2s in the presence or absence of ICOSL blocking antibody and assessed IL-5 and IL-13 cytokine production by ILC2s after 48 hours (Fig 5, C) . Given that ICOS 2/2 ILC2s are only capable of expressing ICOSL, the only possible interaction between ICOS and ICOSL in this system involves ICOSL from ILC2s and ICOS on Treg cells. As shown in Fig 5, C, adding anti-ICOSL blocking antibody to cocultures of iTreg cells and ICOS 2/2 ILC2s abrogated suppression of cytokine production observed with iTreg cells. Thus ICOS-ICOSL interaction, specifically ICOS on iTreg cells and ICOSL on ILC2s, is necessary for contact-dependent suppression of ILC2 activation by iTreg cells, which is consistent with previous findings of our group showing the necessity of ICOS-ICOSL signaling for ILC2 survival and cytokine production. 11 Overall, these data suggest a model whereby Treg cells use ICOSL expression to find and then suppress ILC2s through membrane TGF-b. (Fig 5, B) or ICOS
2/2
ILC2s (Fig 5, C) . After 48 hours, IL-5 and IL-13 levels were measured by using ELISA. Data are presented as means 6 SEMs (n 5 4). *P < .05, **P < .01, ***P < .001, and ****P < .0001. . Data are presented as means 6 SEMs (n 5 4). *P < .05, **P < .01, ***P < .001, and ****P < .0001.
Suppression of human ILC2s by human iTreg cells requires ICOS-ICOS ligand interaction
Similar to mouse ILC2s, 48-hour coculture of human ILC2s with donor-matched human iTreg cells and isotype control antibody reduced production of IL-5 and IL-13, which is dependent on the number of Treg cells added (Fig 6, A) . In all 4 subjects this suppressive effect was abolished in the presence of anti-ICOSL antibodies, which was calculated as percentage suppression of IL-5 or IL-13 production when compared with control values (Fig 6, B) . In the absence of Treg cells, addition of anti-ICOSL to ILC2s reduced IL-5 and IL-13 production compared with isotype control values. As described by our group before, ILC2s express both ICOS and ICOSL, and this interaction provides additional stimulation for ILC2s. 4, 11 However, the suppressive effect of Treg cells was abrogated in the presence of anti-ICOSL antibodies.
Finally, to substantiate the findings from our in vitro experiments, we investigated the role of ICOS-ICOSL interaction in suppression of human ILC2-mediated induction of AHR by human iTreg cells in vivo. Using our recently developed humanized model, 11 we adoptively transferred human ILC2s, human iTreg cells, or both into immunodeficient NSG mice before rhIL-33 challenge to drive AHR (scheme in Fig 7, A) . Transfer of ILC2s alone drove substantial airway constriction as expected, whereas additional cotransfer of Treg cells substantially suppressed AHR (Fig 7, B, left panel) . This effect was specific to iTreg cells because transfer of other CD4
1 T cells (Teff cells) alongside ILC2s did not affect AHR. Similarly, eosinophilia in BAL fluid was attenuated with iTreg cell cotransfer but not CD4
1 Teff cell cotransfer (Fig 7, B, right panel) . To determine the role of ICOSL in our humanized murine model, we used human anti-ICOSL blocking antibody treatment after adoptive transfer of human ILC2s and iTreg cells, followed by IL-33 challenge in alymphoid recipients. We and others reported several years ago that blocking ICOS-ICOSL interaction reduces airway inflammation and AHR. 4, 23, 24 In confirmation of our previous results, here we also observed that blocking ICOS-ICOSL interaction with anti-ICOSL reduced AHR and eosinophilia. However, the addition of iTreg cells suppresses AHR and eosinophilia further, and the suppression effect of iTreg cells was abrogated when the recipients were treated with anti-ICOSL blocking antibody (Fig 7, C) . These results confirm that suppression of human ILC2s by iTreg cells is indeed ICOS-ICOSL dependent in vivo and is sufficient to modulate airway inflammatory disease.
DISCUSSION
In this study we describe the novel and marked ability of iTreg cells to regulate ILC2s both in vitro and in vivo. The balance between Treg cells and type 2 immunity can determine the severity of asthmatic disease, 25 in which Treg cells are known to dampen both dendritic cell and T-cell responses. 26 Here, we add ILC2s as direct Treg cell targets.
Treg cells are divided into nTreg and iTreg cells based on the location of their development, and mice deficient in the peripherally generated iTreg cells have been shown to develop allergic inflammation in their gastrointestinal tracts and lungs. 13, 27 Our data show that iTreg cells, but not nTreg cells, have the ability to regulate lung ILC2s. Precise functional differences between Treg cell subtypes remain unclear; however, iTreg cells have large amounts of membrane-bound TGF-b1 in comparison with nTreg cells, as demonstrated by the expression of LAP in Fig 3, D, and described by others, 15, 28 and iTreg cells can also be better positioned in peripheral tissues in vivo to suppress tissue resident innate lymphoid cells.
Prior studies suggest iTreg cells, as opposed to nTreg cells, are important in suppressing T cell-driven responses in murine asthmatic models. 29, 30 As potent producers of IL-5 and IL-13, ILC2s play a central role in the induction of AHR in the murine model of allergic inflammation in vivo. 5, 31, 32 Here, in one such model, A alternata-sensitized Rag2-deficient mice, transfer of iTreg cells reduced both AHR and eosinophilia, thus suppressing ILC2-dependent inflammation in vivo.
Treg cells use multiple mechanisms to suppress target cells, including suppressive cytokine secretion, contact inhibition, and IL-2 sequestration. 33, 34 We found that IL-10 and TGF-b1 were integral for iTreg cell-mediated ILC2 suppression, with the TGF-b1 effect dominating. This is unsurprising considering the high levels of surface TGF-b1 present on iTreg cells compared with nTreg cells, and indeed, oral and airway tolerance of OVA-driven airway inflammation requires TGF-b1-mediated iTreg cell induction and function but not nTreg cell function. 35, 36 However, it has also been shown that the suppressive abilities of iTreg cells, but not nTreg cells, in murine models of asthma are sensitive to IL-10 neutralization when generated by IL-10-secreting dendritic cells. 30 In these models iTreg cells in peripheral tissues are recruited by and suppress targets with the same antigen specificity. Consistent with our data, several groups recently reported a high level of IL-10 receptor on murine ILC2s and that IL-10 significantly suppresses IL-5 and IL-13 levels in activated ILC2s on IL-33 stimulation. 37, 38 Interestingly, IL-10 did not suppress IL-2-or IL-25-mediated stimulation of activated ILC2s in vitro, suggesting very specific cross-talk between the activating and suppressive pathways that exist in ILC2s. Importantly, we showed that iTreg cells retain the ability to suppress ILC2s activated by IL-33, IL-25, or TSLP.
Interestingly, we found iTreg cells require cellular contact to suppress ILC2s. Because ILC2s do not have specific T-cell receptors, we suggest that the underlying mechanism could be ICOS-ICOSL interaction. Antibody against ICOSL resulted in decreased suppression of cytokines in cocultures of iTreg cells and ILC2s. We have previously shown that ICOS-ICOSL interaction in cis on ILC2s promotes the survival and function of these cells and that Treg cells might disrupt this interaction. Furthermore, administration of blocking antibody against ICOSL in the coculture of ICOS-deficient ILC2s with iTreg cells resulted in decreased IL-5 and IL-13 production, confirming that trans ICOS-ICOSL interaction between these cells does occur. The data also suggest the mechanism of suppression is not through withdrawal of ICOS survival signals on ILC2s but rather through iTreg cell-TGF-b signaling. Therefore the interaction of ICOSL on ILC2s with ICOS on iTreg cells is necessary for iTreg cell-mediated suppression.
To extend the relevance of our findings to human disease, we repeated experiments using human cells and human anti-ICOSL both in vitro and in vivo. Our data show evolutionary conservation of ICOSL-dependent ILC2 suppression by iTreg cells in human subjects in vitro. By using a humanized murine model, we validated ICOS-mediated iTreg cell suppression of human ILC2s in vivo.
ILC2s and Treg cells are important in the study of asthma because Treg cells suppress ILC2s and their production of cytokines, which exacerbate atopic diseases. Indeed, therapeutic Treg cell expansion can limit T cell-driven lung inflammation. 39 The mechanism by which iTreg cells induce suppression of ILC2s is contact dependent and requires ICOS-ICOSL interaction alongside the canonical suppressive molecules IL-10 and TGF-b. Importantly, adoptive transfer of iTreg cells suppressed ILC2-dependent AHR in both murine and humanized murine models in vivo. In vivo blockade of ICOS diminished lung inflammation and reduced ex vivo production of type 2 cytokines. Our data suggest a mechanism by which Treg cells regulate ILC2 function in vivo and open avenues for potential treatment of asthmatic disease.
Clinical implications: Our data illustrate a mechanism by which ILC2s engage in crosstalk with Treg cells. This interaction is required for suppression of ILC2s, opening avenues for potential treatment of ILC2-associated airway inflammation and asthma. Data are expressed as means 6 SEMs (n 5 5). **P < .01, ***P < .001, and ****P < .0001.
